This is a preview of subscription content, log in via an institution to check access.
References
Forcina A, Noviello M, Carbone MR, Bonini C, Bondanza A . Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers. Front Immunol 2013; 4: 71.
Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. Blood 2013; 122: 3359–3364.
Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010; 116: 1655–1662.
Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS ONE 2012; 7: e41648.
Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489–500.
Peccatori FA, Clerici D, Crocchiolo R, Vago L, Lupo Stanghellini MT, Noviello M et al. Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 2014; 29: 396–405.
Ljungman P, Brandan R . Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors. Haematologica 2007; 92: 1139–1142.
Sylwester AW, Mitchell BL, Edgar JB, Taormina C, Pelte C, Ruchti F et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673–685.
Scrucca L, Santucci A, Aversa F . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381–387.
Abate D, Cesaro S, Cofano S, Fiscon M, Saldan A, Varotto S et al. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 2012; 93: 536–542.
Ohnishi M, Sakurai T, Heike Y, Yamazaki R, Kanda Y, Takaue Y et al. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol 2005; 131: 472–479.
Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013; 122: 1316–1324.
Luetke-Eversloh M, Hammer Q, Durek P, Nordstrom K, Gasparoni G, Pink M et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS pathogens 2014; 10: e1004441.
Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 2012; 189: 5082–5088.
Scheper W, van Dorp S, Kersting S, Pietersma F, Lindemans C, Hol S et al. GammadeltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013; 27: 1328–1338.
Acknowledgements
This work was supported by the Italian Ministry of Health (Transcan Haplo-immune Project to A Bondanza).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CB and VV are employees of MolMed S.p.a. and ChB is a consultant of MolMed S.p.a. The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Noviello, M., Forcina, A., Veronica, V. et al. Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. Bone Marrow Transplant 50, 1262–1264 (2015). https://doi.org/10.1038/bmt.2015.132
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.132
- Springer Nature Limited
This article is cited by
-
Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide
Bone Marrow Transplantation (2020)
-
Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting
Bone Marrow Transplantation (2019)
-
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes
Bone Marrow Transplantation (2016)
-
The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide
Bone Marrow Transplantation (2016)